Results 141 to 150 of about 26,125 (257)

Modified Anti-PstS1 Bi-specific antibodies unlock potent protection against tuberculosis. [PDF]

PLoS Pathog
Akanksha, Bouzeyen R, Watson A, Wiseglass G, Sithole N, Abramovitz L, Ben-Shalom N, Rubinstein R, Javid B, Freund NT.   +9 more
europepmc   +1 more source

Consistency of c‐Met protein overexpression over time in patients with non‐squamous non‐small cell lung cancer

Histopathology, EarlyView.
c‐Met protein overexpression can be assessed before or after treatment in patients with non‐squamous NSCLC since most patients maintain a consistent c‐Met status. However, as targeted therapies may elevate c‐Met overexpression, retesting may be necessary for subsets of patients.
Alexis B Cortot, Romain Dubois, Valérie Grégoire, Jean‐Baptiste Gibier, Julien Labreuche, Virginie Deprez, Déborah Dubrulle, Thomas Chretien, Eric Wasielewski, Hélène Behal, Dai Feng, Amber Lind, Peter Ansell, Raphaële Thiébaut‐Millot, Carlos Hader   +14 more
wiley   +1 more source

Editorial: Understanding and controlling adverse effects in myeloma patients treated with T cell redirecting immunotherapies. [PDF]

Front Immunol
Krejcik J, Sponaas AM, Mutis T.
europepmc   +1 more source

Safely targeting combination TNF and IL-23 using a gut-restricted and orally delivered therapeutic approach: proof-of-concept for the development of SOR102 in ulcerative colitis. [PDF]

Transl Gastroenterol Hepatol
Faggiani I, Panaccione R, Ma C.
europepmc   +1 more source

Pathophysiology and emerging treatments for dermographic, cholinergic and cold urticaria

Journal of the European Academy of Dermatology and Venereology, EarlyView.
This review illustrates key proposed mast cell‐mediated activation pathways in dermographic, cholinergic and cold urticaria, highlighting IgE‐dependent and ‐independent mechanisms. These pathways are increasingly targeted by emerging drugs, aiming to interrupt mast cell activation and mediator release, offering more precise, mechanism‐based treatment ...
Mojca Bizjak‐Suran, Matjaž Fležar, Manuel Pedro Pereira   +2 more
wiley   +1 more source

Improving Gallbladder Cancer Outcomes with Antibody-Based Therapies and Immunological Profiling: A Literature Review. [PDF]

Antibodies (Basel)
Caglevic C, Contreras-Torrez MA, Reyes-Cosmelli F, Uribe-Maturana R, Mahave M, Caire N, Villanueva-Olivares L, Cid F, Lladser A, Sapunar J.   +9 more
europepmc   +1 more source

Toxoplasmosis Beyond Transplantation: Diagnostic and Prevention Challenges in a Patient Receiving Targeted Immunomodulators

Transplant Infectious Disease, EarlyView.
ABSTRACT Toxoplasmosis has long been recognized as a serious complication in immunocompromised host, particularly those with advanced HIV/AIDS, hematopoietic stem‐cell transplantation (HSCT), solid‐organ transplant (SOT), and hematological malignancies. The rapid expansion of targeted immunomodulators, including chimeric antigen receptor T‐cell (CAR‐T)
Joy Mouanes‐Abelin, Christelle Pomares, José G. Montoya, Morgane Pondrom, Lucille DE MARIA, Andrea J. Zimmer, Carlos A. Gomez   +6 more
wiley   +1 more source

Bispecific antibodies targeting herpes simplex virus glycoproteins B and D. [PDF]

Front Immunol
Atanasiu D, Saw WT, Cairns TM, Friedman HM, Cohen GH.   +4 more
europepmc   +1 more source

Efficacy and safety of BCMA- or GPRC5D-directed CD3 bispecific antibodies in relapsed/refractory multiple myeloma: a systematic review and meta-analysis of prospective clinical trials and real-world studies. [PDF]

Front Immunol
Li J, Abulaiti A, Li D, Zhao Y, Wahafu P, Maimaitiming M, Qiu S, Zhang Y, An Y, Wang W, Shi L, Yakufu M, Shu L, Li G, Liu Z.   +14 more
europepmc   +1 more source

Sequential Use of Recombinant Porcine Factor VIII and Early Emicizumab in Acquired Hemophilia A: A Case Series

eJHaem, Volume 7, Issue 4, August 2026.
ABSTRACT Background Acquired hemophilia A (AHA) is a rare autoimmune bleeding disorder requiring prompt hemostatic control and sustained prevention of rebleeding. Recombinant porcine factor VIII (rpFVIII, susoctocog alfa) controls acute bleeding, while emicizumab provides prophylaxis. Real‐world data on their sequential use are limited.
Yusuke Yamada, Takashi Onaka, Kazunori Imada   +2 more
wiley   +1 more source